Douglas Tsao

“I guess just maybe as a starting point, I think it'd be helpful to sort of hear your thoughts on sort of the near-term commercial portfolio. So, I mean, Florisync and Dare to Play as well as Dare to Reclaim.”

“Just following up on the telehealth initiative, I'm just curious, Frank, sort of what the conversion rate from an initial online intake to a prescription for ZoraEase?”

“Marcio, maybe there's a little bit of a follow-up on that last question in terms of relutrogene, and then I have a follow-up on vomatrogene, but just sort of when you anticipate utilization, do you see sort of utility across the entire D spectrum and even in indications where there are sort of ASOs or sort of more…”

“I'm just curious, you know, when we look at, I think it's slide 11, and you obviously, you know, as writers or as doctors write more for more indications, you sort of get a real economy of scale or sort of, you know, sort of logarithmic effect in terms of the scripts that they're writing, how, you know, how long does…”

“Now that you've added your own internal R&D capabilities in discovery and IO, I'm just curious: as you add these capabilities, how do you see your vision for growing the business versus business development?”